Christopher G. Hayes

CIK: 0001805359

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (25.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VRCA

Verrica Pharmaceuticals Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (4 total)

VRCA
Verrica Pharmaceuticals Inc.
Mar 17, 2025
Sale(S)
Direct
4.3K shares at avg. $0.65$3K
VRCA
Verrica Pharmaceuticals Inc.
Mar 14, 2025
Award(A)
Employee Stock Option (right to buy)
Direct
250K shares-
VRCA
Verrica Pharmaceuticals Inc.
Oct 9, 2024
Award(A)
Employee Stock Option (right to buy)
Direct
50K shares-
VRCA
Verrica Pharmaceuticals Inc.
Aug 24, 2023
Award(A)
Direct
150K shares-

		Type	Shares	Price		Ownership
Mar 17, 2025	VRCA Verrica Pharmaceuticals Inc.	Sale(S)	4,315	$0.65	$2,805	Direct
Mar 14, 2025	VRCA Verrica Pharmaceuticals Inc.	Award(A) Employee Stock Option (right to buy)	250,000	-	-	Direct
Oct 9, 2024	VRCA Verrica Pharmaceuticals Inc.	Award(A) Employee Stock Option (right to buy)	50,000	-	-	Direct
Aug 24, 2023	VRCA Verrica Pharmaceuticals Inc.	Award(A)	150,000	-	-	Direct

1-4 of 4 transactions

About Hayes Christopher G.

Hayes Christopher G. (SEC CIK 0001805359) files insider reports with the SEC as CHIEF LEGAL OFFICER of Verrica Pharmaceuticals Inc. (VRCA).

Signal8 holds 3 ownership filings by Hayes Christopher G., all Form 4s, filed between Oct 11, 2024 and Mar 18, 2025. Those filings report 4 transactions, from Aug 24, 2023 to Mar 17, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Hayes Christopher G.'s filings is in WEST CHESTER, PA.

Recent filings by Hayes Christopher G.

Mar 17, 2025: Open-market sale of VRCA shares (Form 4, code S).
Mar 14, 2025: Grant or award of VRCA derivative securities (Form 4, code A).
Oct 9, 2024: Grant or award of VRCA derivative securities (Form 4, code A).
Aug 24, 2023: Grant or award of VRCA shares (Form 4, code A).

Other insiders filing for Verrica Pharmaceuticals Inc. (VRCA)

Zawitz David, Chief Operating Officer
Rieger Jayson, CEO and President
Rosenberg Noah L., CMO
Kirby John J., Interim CFO
Eichenfield Lawrence, Director
Nguyen Diem, Director

How to read Form 4 transaction codes